Working... Menu

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03762759
Recruitment Status : Recruiting
First Posted : December 4, 2018
Last Update Posted : July 29, 2019
Telix International Pty Ltd
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ashesh B Jani, MD, Emory University

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 31, 2025
  Estimated Study Completion Date : December 31, 2025